Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Lojuxta lomitapide regulatory update

The European Commission approved an MAA from Aegerion for Lojuxta lomitapide to treat homozygous familial hypercholesterolemia (hoFH).

Read the full 175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE